Lynn Seely, Myovant CEO (File photo)
December 28, 2020 08:14 AM EST
Deals

Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

John Carroll

Editor & Founder

My­ovant $MY­OV is ring­ing out the old year with a big, new com­mer­cial part­ner.

Pfiz­er $PFE has stepped up with a $4.2 bil­lion deal to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times